Skip to main content
Oncotarget logoLink to Oncotarget
. 2021 Aug 17;12(17):1736. doi: 10.18632/oncotarget.28051

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

Teru Hideshima 1, Ralph Mazitschek 2, Jun Qi 1, Naoya Mimura 1,5, Jen-Chieh Tseng 3,6, Andrew L Kung 3,4,7, James E Bradner 1,8, Kenneth C Anderson 1,
PMCID: PMC8378766  PMID: 34434504

This article has been corrected: The CONFLICTS OF INTERESTS section has been updated as shown below:

CONFLICTS OF INTEREST

K.C. Anderson is on the advisory board of Celgene, Gilead, Millennium and Bristol Myers Squibb; and is a scientific founder with financial interest in Acetylon, Oncopep and C4 Therapeutics. JB is a scientific founder with financial interest in Acetylon.

Original article: Oncotarget. 2017; 8:80109–80123. 80109-80123. https://doi.org/10.18632/oncotarget.19019


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES